Table 2.

Demographic and clinical characteristics by cognitive impairment status.

	Cognitively impaired (n = 13)	Cognitively normal (n = 11)	p-value
Age (years)	69.8 (5.9)	73.1 (4.9)	0.15
Sex (% female)	38.5%	45.5%	0.73
Education (years)	15.0 (2.6)	16.6 (1.7)	0.09
Neurological diagnosis
PD	10	8
PSP	2	3
MSA	1	0
Disease duration (years)	8.3 (5.7)	10.1 (11.5)	0.63
UPDRS Part III score	28.2 (11.4)	29.9 (12.4)	0.73
Presence of dyskinesia (% with)	15.4%	18.1%	0.87
Medication use (% taking)
Amantadine	15.4%	18.2%	0.87
MAO-B Inhibitor	30.8%	36.4%	0.48
Trihexiphenidyl	7.7%	0%	0.35
Donepezil	30.8%	0%	0.04
Presence of DBS (% with)	30.8%	9.1%	0.14
NPC (in cm)	18.4 (4.3)	12.5 (4.3)	0.003
Symptomatic CI	61.5%	81.8%	0.23
Subjective cognitive complaints (% reporting)	92.3%	54.5%	0.03
Total SAGE score (max 22)	14.1 (3.6)	19.5 (4.9)	0.006

Data presented as mean (SD) unless otherwise noted. CI, convergence insufficiency; PD, Parkinson's disease; PSP, Progressive supranuclear palsy; MSA, Multiple system atrophy; UPDRS, Unified Parkinson's Disease Rating Scale; DBS, Deep brain stimulation; NPC, Near point of convergence; SAGE, Self-Administered Gerocognitive Exam. Bold values indicates p < 0.05.